News
GRTS
0.8696
-0.47%
-0.0041
Strength in Kidney Care Likely to Aid DaVita's (DVA) Q1 Earnings
NASDAQ · 1d ago
GRITSTONE BIO HIGHLIGHTS THE DURABILITY AND POTENTIAL BROAD UTILITY OF ITS SELF-AMPLIFYING MRNA (SAMRNA) COVID-19 VACCINE AT ESCMID GLOBAL 2024
Reuters · 2d ago
Gritstone Oncology Announces Board of Directors Changes
TipRanks · 3d ago
GRITSTONE BIO ANNOUNCES APPOINTMENT OF STEPHEN WEBSTER TO ITS BOARD OF DIRECTORS
Reuters · 3d ago
Press Release: Gritstone bio Announces Appointment of Stephen Webster to its Board of Directors
Gritstone bio, Inc. Announces appointment of Stephen Webster to its Board of Directors. Webster is a veteran finance executive in the biotechnology industry. The company also announced that Steve Krognes will not stand for re-election at the 2024 Annual Meeting. Gritstone is a clinical-stage biotechnology company working to develop world's most potent vaccines.
Dow Jones · 3d ago
Weekly Report: what happened at GRTS last week (0422-0426)?
Weekly Report · 3d ago
Weekly Report: what happened at GRTS last week (0415-0419)?
Weekly Report · 04/22 09:07
GRITSTONE BIO INC <GRTS.O>: B. RILEY CUTS TARGET PRICE TO $3 FROM $6
Reuters · 04/17 05:48
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study Of "Off-the-Shelf" Neoantigen Vaccine Platform
Paper details vaccine design optimization process of Gritstone's neoantigen vaccine platform. Discovery of a novel immunodominance hierarchy of tumor neoantigens enabled development of KRAS-specific vaccine candidate. Publication underscores the important role of antigen selection and cassette design in the development of immunotherapy.
Benzinga · 04/15 11:15
Weekly Report: what happened at GRTS last week (0408-0412)?
Weekly Report · 04/15 09:07
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
Paper details vaccine design optimization process of Gritstone’s neoantigen vaccine platform, SLATE. Discovery of a novel immunodominance hierarchy of tumor neoantigens enabled the development of a more potent, KRAS-specific vaccine candidate. National Cancer Institute.
Barchart · 04/15 06:00
Buy Rating Affirmed: Gritstone Oncology’s Promising Growth and Technological Advancements
TipRanks · 04/08 18:25
Weekly Report: what happened at GRTS last week (0401-0405)?
Weekly Report · 04/08 09:07
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
Gritstone bio's GRANITE program shows promising preliminary results in the treatment of metastatic microsatellite stable colorectal cancer (MSS-CRC) The company recently announced preliminary data from its cancer vaccine program. The company also announced an offering of shares. Gritstone is a company that is developing a cancer vaccine that could transform cancer treatment. In a previous article, I highlighted the upside potential of Grit stone bio.
Seeking Alpha · 04/07 04:22
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
NASDAQ · 04/04 17:32
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA) and Gritstone Oncology (GRTS)
TipRanks · 04/03 09:32
GRITSTONE BIO INC <GRTS.O>: BTIG CUTS TARGET PRICE TO $3 FROM $20
Reuters · 04/03 04:07
Nasdaq Down Over 1%; VivoPower International Shares Spike Higher
U.S. Stocks traded lower toward the end of trading on Tuesday. The Dow traded down 1.07% while the NASDAQ fell 1.14%. The number of job openings rose by 8,000 from the prior month to 8.756 million in February. Energy shares jumped by 0.6% on Tuesday; health care shares fell by 2%. European shares closed lower today.
Benzinga · 04/02 18:45
Gritstone bio Is Maintained at Market Outperform by JMP Securities
Dow Jones · 04/02 18:19
Gritstone bio Price Target Raised to $5.00/Share From $4.00 by JMP Securities
Dow Jones · 04/02 18:19
More
Webull provides a variety of real-time GRTS stock news. You can receive the latest news about Gritstone Bio Inc through multiple platforms. This information may help you make smarter investment decisions.
About GRTS
Gritstone bio, Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. It has developed two vectors that it deploys with the aim of eliciting the desired immune response: self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd). Its two oncology programs in clinical-stage development are GRANITE, individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. It has an infectious disease pipeline, which includes two programs in clinical-stage development: CORAL, a second-generation COVID-19 vaccine program that may have pan-coronavirus potential to protect against future coronavirus pandemics, and an HIV therapeutic/cure vaccine candidate. In oncology, it develops personalized vaccines that aim to destroy tumors through CD8+ (killer) T cell recognition of tumor cells by virtue of their surface display of neoantigens.